caseism

Recovering Abandoned Compounds Through Expanded External IP Licensing Case Solution & Answer

The development costs of pharmaceutical products have increased rapidly in the last twenty years. However, the number of new molecular entities are approved has not been increased. Most of these costs are attributable to work in compounds that are abandoned before reaching the market. While pharmaceutical companies reduce their work taking into account the deterioration of the productivity of R & D, unmet medical needs remain unanswered. Larger external licensing the IP address associated with abandoned compounds could stimulate recovery and / or rehabilitation of abandoned to solve at least some of these compounds unmetmedical needs. The example of Cubicin is provided as an illustration of thesemore open approaches. This paper presents a simple framework leads to guide companies to decide whether and when to dismiss internal IP used is developed.
by
Henry Chesbrough,
Eric L. Chen
Source: California Management Review
19 pages.
Publication Date: August 1, 2013. Prod #: CMR546-PDF-ENG
Collect abandoned compounds Expanded Solution In case of external IP licenses

Share This

LOOK FOR A FREE CASE STUDY SOLUTION

JUST REGISTER NOW AND GET 50% OFF ON EACH CASE STUDY